Projected life expectancy of people with HIV according to timing of diagnosis

AIDS. 2012 Jan 28;26(3):335-43. doi: 10.1097/QAD.0b013e32834dcec9.


Background and objectives: Effective antiretroviral therapy (ART) has contributed greatly toward survival for people with HIV, yet many remain undiagnosed until very late. Our aims were to estimate the life expectancy of an HIV-infected MSM living in a developed country with extensive access to ART and healthcare, and to assess the effect of late diagnosis on life expectancy.

Methods: A stochastic computer simulation model of HIV infection and the effect of ART was used to estimate life expectancy and determine the distribution of potential lifetime outcomes of an MSM, aged 30 years, who becomes HIV positive in 2010. The effect of altering the diagnosis rate was investigated.

Results: Assuming a high rate of HIV diagnosis (median CD4 cell count at diagnosis, 432 cells/μl), projected median age at death (life expectancy) was 75.0 years. This implies 7.0 years of life were lost on average due to HIV. Cumulative risks of death by 5 and 10 years after infection were 2.3 and 5.2%, respectively. The 95% uncertainty bound for life expectancy was (68.0,77.3) years. When a low diagnosis rate was assumed (diagnosis only when symptomatic, median CD4 cell count 140 cells/μl), life expectancy was 71.5 years, implying an average 10.5 years of life lost due to HIV.

Conclusion: If low rates of virologic failure observed in treated patients continue, predicted life expectancy is relatively high in people with HIV who can access a wide range of antiretrovirals. The greatest risk of excess mortality is due to delays in HIV diagnosis.

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Computer Simulation
  • Delayed Diagnosis* / adverse effects
  • HIV Seropositivity / diagnosis
  • HIV Seropositivity / drug therapy
  • HIV Seropositivity / mortality*
  • Health Services Accessibility / statistics & numerical data
  • Homosexuality, Male
  • Humans
  • Life Expectancy
  • Male
  • Practice Guidelines as Topic
  • Survival Rate
  • Time Factors
  • United Kingdom


  • Anti-HIV Agents